Watch HURA. Know when insiders buy.
One email the day a filing lands. Free.
HURA
TuHURA Biosciences, Inc./NV
2.09
+0.33 +18.47%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
52
WATCH · shorts 52
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $132.9MP/E —DIV YIELD —FCF YIELD -22.51%REV TTM —NET INCOME −$30.6MNET DEBT $2.6M52W 0.44 – 3.15SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | — | −$9.2M | — | -0.14 | −$8.6M | $137K | −$8.8M | Aug 14 |
| Q1 2026 · Mar 31 | $0 | — | — | — | −$7.5M | — | -0.13 | −$4.4M | $49K | −$4.5M | Aug 14 |
| Q4 2025 · Dec 31derived | $0 | — | — | — | −$6.8M | — | -0.13 | −$5.6M | $28K | −$5.6M | Mar 31 |
| Q3 2025 · Sep 30 | $0 | — | — | — | −$7.1M | — | -0.14 | −$11.1M | $0 | −$11.1M | Nov 14 |
| Q2 2025 · Jun 30 | $0 | — | — | — | −$9.5M | — | -0.21 | −$6.2M | $6K | −$6.3M | Aug 14 |
| Q1 2025 · Mar 31 | $0 | — | — | — | −$6.7M | — | -0.15 | −$4.7M | $43K | −$4.8M | Aug 14 |
| Q4 2024 · Dec 31derived | $0 | — | — | — | −$6M | — | 0.16 | −$2.6M | $21K | −$2.6M | Mar 31 |
| Q3 2024 · Sep 30 | $0 | — | — | — | −$5.6M | — | -0.54 | −$1.9M | $0 | −$1.9M | Nov 14 |
| Q2 2024 · Jun 30 | $0 | — | — | — | −$5.3M | — | -0.43 | −$1.4M | — | — | Nov 14 |
| Q1 2024 · Mar 31 | $0 | — | — | — | −$4.8M | — | -0.40 | −$3.8M | — | — | Nov 14 |
| Q4 2023 · Dec 31 | — | — | — | — | −$1M | — | -0.24 | −$2.1M | — | — | Feb 14 |
| Q3 2023 · Sep 30 | — | — | — | — | −$3M | — | -63.92 | −$1.3M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | — | −$30.1M | — | -0.63 | −$27.6M | $76K | −$27.7M | — | — |
| FY2024 · to Dec 31 | $0 | — | — | −$21.7M | — | -1.21 | −$14.7M | $58K | −$14.8M | — | — |
| FY2024 · to Jun 30 | — | — | — | −$8.3M | — | -0.32 | −$7.2M | — | — | — | — |
| FY2023 · to Dec 31 | $0 | — | — | −$29.3M | — | -2.47 | −$12M | $79K | −$12M | $25K | — |
| FY2023 · to Jun 30 | — | — | — | −$14.6M | — | -9.27 | −$11.9M | — | — | — | — |
| FY2022 · to Jun 30 | — | — | — | −$22.7M | — | -25.80 | −$20.4M | $180K | −$20.6M | — | — |
Every number comes from TuHURA Biosciences, Inc./NV's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.